Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kapil Borawake

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine|October 21, 2011
Dengue encephalitisKapil Borawake, Parikshit Prayag, Atul Wagh, et al.
The Journal of the Association of Physicians of India|July 14, 2022
Retrospective Cohort Observational Study to compare the Effect of Mycobacterium w along with Standard of Care vs Standard of Care alone in critically ill COVID-19 PatientsSubhal Dixit, Kapil Zirpe, Prasad Suryawanshi, et al.
Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine|March 3, 2023
Noninvasive Respiratory Assist Devices in the Management of COVID-19-related Hypoxic Respiratory Failure: Pune ISCCM COVID-19 ARDS Study Consortium (PICASo)Sameer Jog, Kapil Zirpe, Subhal Dixit, et al.
Critical Care (London, England)|November 20, 2024
A multicentre prospective registry of one thousand sepsis patients admitted in Indian ICUs: (SEPSIS INDIA) studySubhash Todi, Yatin Mehta, Kapil Zirpe, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis planM W Munch, Anders Granholm, S N Myatra, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysisAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trialAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemiaAnders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
JAMA|October 21, 2021
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial, Marie W Munch, Sheila N Myatra, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine|October 21, 2011
Dengue encephalitisKapil Borawake, Parikshit Prayag, Atul Wagh, et al.
The Journal of the Association of Physicians of India|July 14, 2022
Retrospective Cohort Observational Study to compare the Effect of Mycobacterium w along with Standard of Care vs Standard of Care alone in critically ill COVID-19 PatientsSubhal Dixit, Kapil Zirpe, Prasad Suryawanshi, et al.
Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine|March 3, 2023
Noninvasive Respiratory Assist Devices in the Management of COVID-19-related Hypoxic Respiratory Failure: Pune ISCCM COVID-19 ARDS Study Consortium (PICASo)Sameer Jog, Kapil Zirpe, Subhal Dixit, et al.
Critical Care (London, England)|November 20, 2024
A multicentre prospective registry of one thousand sepsis patients admitted in Indian ICUs: (SEPSIS INDIA) studySubhash Todi, Yatin Mehta, Kapil Zirpe, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis planM W Munch, Anders Granholm, S N Myatra, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysisAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trialAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemiaAnders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
JAMA|October 21, 2021
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial, Marie W Munch, Sheila N Myatra, et al.
Pageof 1